Efficacy and effectiveness of influenza vaccine and pneumococcal conjugated vaccine - 13 (PCV13) in patients with chronic kidney disease

Not Applicable

• Conditions: chronic kidney disease; Influenza vaccine; 13- valent pneumococcal vaccine; chronic kidney diseases; pneumonia

• Registration Number: TCTR20160609002
• Lead Sponsor: Queen Saovabha Memorial Institute, the Thai Redcross society

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-06-09
• Study Completion: 2019-07-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 1584

Inclusion Criteria

1. Chronic kidney disease stage 3 - 5

Exclusion Criteria

1. Allergic to influenza vaccine and/or PCV13

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
community—acquired pneumonia from any cause 3 years vaccine efficacy

Secondary Outcome Measures

Name	Time	Method
hospitalization from pneumonia from any cause 3 years vaccine efficacy,respiratory failure from respiratory tract infection from any cause 3 years vaccine efficacy,ICU admission from respiratory tract infection from any cause 3 years vaccine efficacy,mortality from any cause 3 years vaccine efficacy,enzyme-linked immunospot (ELISPOT) assay for influenza immune response 3 years vaccine efficacy,incidence of pneumococcal pneumonia 3 years vaccine efficacy,incidence of invasive pneumococcal disease 3 years vaccine efficacy,mortality from invasive pneumococcal disease 3 years vaccine efficacy